We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Drugs that go beyond the rule of five – or do they?
News

Drugs that go beyond the rule of five – or do they?

Drugs that go beyond the rule of five – or do they?
News

Drugs that go beyond the rule of five – or do they?

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Drugs that go beyond the rule of five – or do they?"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

rscimage1.gif

Lipinski’s rule of five is probably one of the first principles taught to a medicinal chemist, as it defines the chemical space likely to yield a successful oral drug. However, in recent years some drugs have moved beyond traditional rule of five space in order to access alternative or challenging targets.

By determining the propensity of molecules to form intramolecular hydrogen bonds David S. Millan and colleagues at Pfizer R&D are able to revise previous assumptions about where certain molecules sit in chemical space.  They find that when hydrogen bonding is taken into account these drugs sit much closer to rule of five space – thereby explaining the successful absorption of drugs that otherwise violate rule of five principles.

Reproduced by permission from The Royal Society of Chemistry from MedChemComm Blog at http://blogs.rsc.org/md

Advertisement